2025年度公司整体仍未能实现盈利，主要因为上药罗欣业绩持续未达预期，公司确认了相关金融负债的 公允价值变动损失，该损失属于非经常性损益，最终金额将由公司聘请的审计机构进行审计后确定。公 司虽已启动对乐康制药、罗欣安若维他相关亏损业务的处置程序，但其在出售完成前的经营亏损仍对公 司本期业绩产生一定拖累。随着处置完毕，其亏损影响将减少。 近日，罗欣药业（002793）发布公告称，预计2025年度归母净利润约-3.4亿元至-2.5亿元，上年同期为 亏损9.65亿元。 公告指出，业绩变动的主要原因是公司继续战略性聚焦医药工业板块，特别是具有优势的消化系统领 域，在公司核心创新药产品替戈拉生片（商品名：泰欣赞 ）快速增长的拉动下，产品结构和增长质量 持续提升。 ...

业绩变动的主要原因包括受市场需求和自产试剂产品增值税税率调整的影响，公司营业收入减少；同 时，在报告期内，公司积极采取各项开源节流举措，提升精细化经营能力，但因公司运营成本、人力成 本等固定成本开支较大，收入规模下降幅度短期内难以匹配成本下降幅度，对公司综合毛利造成负面影 响，导致本年度出现经营亏损。 近日，达安基因（002030）发布公告称，预计2025年度归母净利润约亏损6.07亿-8.65亿元，较上年同期 的亏损9.25亿元有所改善。 公告同时提到，报告期内，公司联营企业的业绩较上年同期好转，公司对联营企业确认的投资收益较上 年同期增加，归属于上市公司股东的净利润较上年同期增加。 ...

2月2日，好想你在投资者互动平台上表示，公司近期经营情况正常，公司股价波动受多重市场因素影 响，不存在应披露而未披露的重大信息。公司请投资者理性看待市场波动，公司更注重内在价值的提 升，未来将持续以扎实的业绩回报投资者。 （深交所互动易） (编辑：王璨 林辰)关键字： 食品 好想你 ...

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 2月2日，据汇华理财披露，该公司发行的趋势指南封闭式固定收益类理财产品2602期认购期2026年2月2 日至2026年2月11日。认购起点金额人民币1元，募集规模上限人民币50亿元。产品类型为固定收益类， 存续期限350天，业绩比较基准为2.48%-3.10%（年化）。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

2月2日，农业银行（601288）发布关于进一步做好贵金属市场风险防范的提示。农业银行表示，近期国 内外贵金属市场价格波动剧烈，不确定性因素显著增强。特别提示各位客户审慎评估自身风险承受能 力，综合考虑自身财务状况开展贵金属交易业务，保持理性投资心态。请各位客户密切关注行情变化， 合理控制持仓规模，有效防范市场波动风险。 ...

巨力索具公告，控股股东巨力集团于2026年1月30日质押708万股，占其持股3.68%、占公司总股本 0.74%，质权人为中国银河证券股份有限公司，质押期限至2027年1月29日；实际控制人杨会德同期质 押783万股，占其持股46.61%、占公司总股本0.82%，合计质押1491万股，占公司总股本1.55%。截至公 告日，控股股东及一致行动人累计质押5325万股，占公司总股本5.55%。 ...

深圳市投资控股有限公司公告，公司下属子公司英飞拓及其全资子公司英飞拓仁用、英飞拓智能、英飞 拓软件和英飞拓智园发生部分债务逾期，英飞拓为全资子公司向银行借款提供连带责任保证担保，英飞 拓担保逾期。截至2026年1月27日，英飞拓债务逾期本金及逾期未付利息合计8514.27万元。另外，英飞 拓为子公司向银行借款提供连带责任保证担保，英飞拓担保逾期，逾期金额4412.03万元。英飞拓正积 极与债权机构沟通，探讨切实可行的解决方案。 ...

北京华业资本控股股份有限公司公告，执行安徽省合肥市中级人民法院(2024)皖01执恢60号之二《执行 裁定书》后，被执行人华业发展(深圳)有限公司(以下简称"华业发展")持有的北京华业资本控股股份有 限公司的1.32亿股股票，已通过执行法院裁定形式过户至国元证券股份有限公司(以下简称"国元证 券")。本次股份过户后，挂牌公司无控股股东，第一大股东发生变更，由华业发展变更为国元证券，不 存在新增一致行动人。 ...

Group 1 - The core point of the article is that Xiaohongshu has become the exclusive interactive community for the 2026 Spring Festival Gala, allowing users to engage in discussions and activities while watching the event [1][3] - During the live broadcast, users can participate in interactive searches on Xiaohongshu to receive lucky envelopes and have the chance to win a total of 250,000 "New Year Red Boxes" [1][3] - Xiaohongshu aims to enhance community interaction and explore innovative collaboration models in the media era, building a warm and engaging festive atmosphere [3][4] Group 2 - The platform will introduce various Spring Festival-themed activities, including a "Spring Festival Guide" for practical information on travel and meals, and interactive features like "Annual Poetry" and "Book of Answers" [3] - Users can share their Spring Festival moments through posts, voice greetings, and participate in a voice party in the comments section, fostering a sense of community [3][4] - Last year, during the Spring Festival Gala, Xiaohongshu recorded over 1.4 billion interactions related to the event, highlighting the platform's strong community engagement [3]

Core Viewpoint - Junshi Biosciences expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year growth of about 28.32% [1] Revenue and Profit Forecast - The projected R&D expenses are estimated at 1.353 billion yuan, an increase of approximately 6.10% compared to the previous year [1] - The expected net profit attributable to shareholders is a loss of approximately 873 million yuan, which is a reduction in losses compared to the previous year [1] - After excluding the impact of share-based payments, the expected net profit attributable to shareholders is a loss of about 799 million yuan, reflecting a year-on-year decrease in losses of approximately 37.62% [1] - The expected net profit attributable to shareholders, after excluding non-recurring gains and losses, is a loss of about 985 million yuan, which is a reduction in losses of approximately 23.64% [1] Revenue Growth Drivers - The growth in revenue is primarily attributed to the significant increase in sales of the core product, Toripalimab injection (Tuoyi®), in the domestic market [1] - Tuoyi® has been approved for 12 indications, all of which are included in the national medical insurance catalog, and has been approved for sale in multiple countries and regions globally [1] Cost Management and Future Plans - Despite the continued net loss, the company has significantly narrowed the loss amount, mainly due to ongoing efforts in quality improvement and cost control [1] - The company plans to accelerate the clinical trials of several innovative drugs that have competitive advantages in international markets [1]